Progress in the Treatment of Alzheimer's Disease Is Needed -
Position Statement of European Alzheimer's Disease Consortium
(EADC) Investigators

J 2024

Progress in the Treatment of Alzheimer's Disease Is Needed - Position Statement of European Alzheimer's Disease Consortium (EADC) Investigators

JESSEN, Frank, M. G. KRAMBERGER, D. ANGIONI, D. AARSLAND, M. BALASA et. al.

Základní údaje

Originální název

Progress in the Treatment of Alzheimer's Disease Is Needed - Position Statement of European Alzheimer's Disease Consortium (EADC) Investigators

Autoři

Vydání

JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, BASEL, SPRINGER BASEL AG, 2024, 2274-5807

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30210 Clinical neurology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.400 v roce 2022

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.14283/jpad.2024.153

UT WoS

001290671000001

Klíčová slova anglicky

Alzheimer's disease; mild cognitive impairment; disease modifying treatment; beta-amyloid-targeting treatment; amyloid imaging related abnormalities

Štítky

14110127, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 5. 11. 2024 14:36, Mgr. Tereza Miškechová

Anotace

V originále

Beta-amyloid-targeting antibodies represent the first generation of effective causal treatment of Alzheimer's disease (AD) and can be considered historical research milestones. Their effect sizes, side effects, implementation challenges and costs, however, have stimulated debates about their overall value. In this position statement academic clinicians of the European Alzheimer's Disease Consortium (EADC) discuss the critical relevance of introducing these new treatments in clinical care now. Given the complexity of AD it is unlikely that molecular single-target treatments will achieve substantially larger effects than those seen with current beta-amyloid-targeting antibodies. Larger effects will most likely only be achieved incrementally by continuous optimization of molecular approaches, patient selection and combinations therapies. To be successful in this regard, drug development must be informed by the use of innovative treatments in real world practice, because full understanding of all facets of novel treatments requires experience and data of real-world care beyond those of clinical trials. Regarding the antibodies under discussion we consider their effects meaningful and potential side effects manageable. We assume that the number of eventually treated patient will only be a fraction of all early AD patients due to narrow eligibility criteria and barriers of access. We strongly endorse the use of these new compound in clinical practice in selected patients with treatment documentation in registries. We understand this as a critical step in advancing the field of AD treatment, and in shaping the health care systems for the new area of molecular-targeted treatment of neurodegenerative diseases.

Citovat

JESSEN, Frank, M. G. KRAMBERGER, D. ANGIONI, D. AARSLAND, M. BALASA, K. BENNYS, M. BOADA, M. BOBAN, A. CHINCARINI, L. EXALTO, A. FELBECKER, K. FLIESSBACH, G. B. FRISONI, A. J. GARZA-MARTINEZ, T. GRIMMER, B. HANSEEUW, J. HORT, A. IVANOIU, S. KLOPPEL, Lenka KRAJČOVIČOVÁ, B. MCGUINNESS, P. MECOCCI, A. DE MENDONCA, A. NOUS, P -j. OUSSET, C. PAQUET, R. PERNECZKY, O. PETERS, M. TABUAS-PEREIRA, F. PIAZZA, D. PLANTONE, M. RIVEROL, A. RUIZ, G. SACCO, I. SANTANA, N. SCARMEAS, E. SOLJE, E. STEFANOVA, S. SUTOVSKY, W. VAN DER FLIER, T. WELSH, A. WIMO, B. WINBLAD, L. FROELICH a S. ENGELBORGHS. Progress in the Treatment of Alzheimer's Disease Is Needed - Position Statement of European Alzheimer's Disease Consortium (EADC) Investigators. JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE. BASEL: SPRINGER BASEL AG, 2024, roč. 11, č. 5, s. 1212-1218. ISSN 2274-5807. Dostupné z: https://dx.doi.org/10.14283/jpad.2024.153.

@article{2423717,
   author = {Jessen, Frank and Kramberger, M. G. and Angioni, D. and Aarsland, D. and Balasa, M. and Bennys, K. and Boada, M. and Boban, M. and Chincarini, A. and Exalto, L. and Felbecker, A. and Fliessbach, K. and Frisoni, G. B. and GarzaandMartinez, A. J. and Grimmer, T. and Hanseeuw, B. and Hort, J. and Ivanoiu, A. and Kloppel, S. and Krajčovičová, Lenka and McGuinness, B. and Mecocci, P. and de Mendonca, A. and Nous, A. and Ousset, P andj. and Paquet, C. and Perneczky, R. and Peters, O. and TabuasandPereira, M. and Piazza, F. and Plantone, D. and Riverol, M. and Ruiz, A. and Sacco, G. and Santana, I. and Scarmeas, N. and Solje, E. and Stefanova, E. and Sutovsky, S. and van der Flier, W. and Welsh, T. and Wimo, A. and Winblad, B. and Froelich, L. and Engelborghs, S.},
   article_location = {BASEL},
   article_number = {5},
   doi = {http://dx.doi.org/10.14283/jpad.2024.153},
   keywords = {Alzheimer's disease; mild cognitive impairment; disease modifying treatment; beta-amyloid-targeting treatment; amyloid imaging related abnormalities},
   language = {eng},
   issn = {2274-5807},
   journal = {JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE},
   title = {Progress in the Treatment of Alzheimer's Disease Is Needed - Position Statement of European Alzheimer's Disease Consortium (EADC) Investigators},
   url = {https://link.springer.com/article/10.14283/jpad.2024.153},
   volume = {11},
   year = {2024}
}

TY  - JOUR
ID  - 2423717
AU  - Jessen, Frank - Kramberger, M. G. - Angioni, D. - Aarsland, D. - Balasa, M. - Bennys, K. - Boada, M. - Boban, M. - Chincarini, A. - Exalto, L. - Felbecker, A. - Fliessbach, K. - Frisoni, G. B. - Garza-Martinez, A. J. - Grimmer, T. - Hanseeuw, B. - Hort, J. - Ivanoiu, A. - Kloppel, S. - Krajčovičová, Lenka - McGuinness, B. - Mecocci, P. - de Mendonca, A. - Nous, A. - Ousset, P -j. - Paquet, C. - Perneczky, R. - Peters, O. - Tabuas-Pereira, M. - Piazza, F. - Plantone, D. - Riverol, M. - Ruiz, A. - Sacco, G. - Santana, I. - Scarmeas, N. - Solje, E. - Stefanova, E. - Sutovsky, S. - van der Flier, W. - Welsh, T. - Wimo, A. - Winblad, B. - Froelich, L. - Engelborghs, S.
PY  - 2024
TI  - Progress in the Treatment of Alzheimer's Disease Is Needed - Position Statement of European Alzheimer's Disease Consortium (EADC) Investigators
JF  - JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE
VL  - 11
IS  - 5
SP  - 1212-1218
EP  - 1212-1218
PB  - SPRINGER BASEL AG
SN  - 22745807
KW  - Alzheimer's disease
KW  - mild cognitive impairment
KW  - disease modifying treatment
KW  - beta-amyloid-targeting treatment
KW  - amyloid imaging related abnormalities
UR  - https://link.springer.com/article/10.14283/jpad.2024.153
N2  - Beta-amyloid-targeting antibodies represent the first generation of effective causal treatment of Alzheimer's disease (AD) and can be considered historical research milestones. Their effect sizes, side effects, implementation challenges and costs, however, have stimulated debates about their overall value. In this position statement academic clinicians of the European Alzheimer's Disease Consortium (EADC) discuss the critical relevance of introducing these new treatments in clinical care now. Given the complexity of AD it is unlikely that molecular single-target treatments will achieve substantially larger effects than those seen with current beta-amyloid-targeting antibodies. Larger effects will most likely only be achieved incrementally by continuous optimization of molecular approaches, patient selection and combinations therapies. To be successful in this regard, drug development must be informed by the use of innovative treatments in real world practice, because full understanding of all facets of novel treatments requires experience and data of real-world care beyond those of clinical trials. Regarding the antibodies under discussion we consider their effects meaningful and potential side effects manageable. We assume that the number of eventually treated patient will only be a fraction of all early AD patients due to narrow eligibility criteria and barriers of access. We strongly endorse the use of these new compound in clinical practice in selected patients with treatment documentation in registries. We understand this as a critical step in advancing the field of AD treatment, and in shaping the health care systems for the new area of molecular-targeted treatment of neurodegenerative diseases.
ER  -

JESSEN, Frank, M. G. KRAMBERGER, D. ANGIONI, D. AARSLAND, M. BALASA, K. BENNYS, M. BOADA, M. BOBAN, A. CHINCARINI, L. EXALTO, A. FELBECKER, K. FLIESSBACH, G. B. FRISONI, A. J. GARZA-MARTINEZ, T. GRIMMER, B. HANSEEUW, J. HORT, A. IVANOIU, S. KLOPPEL, Lenka KRAJČOVIČOVÁ, B. MCGUINNESS, P. MECOCCI, A. DE MENDONCA, A. NOUS, P -j. OUSSET, C. PAQUET, R. PERNECZKY, O. PETERS, M. TABUAS-PEREIRA, F. PIAZZA, D. PLANTONE, M. RIVEROL, A. RUIZ, G. SACCO, I. SANTANA, N. SCARMEAS, E. SOLJE, E. STEFANOVA, S. SUTOVSKY, W. VAN DER FLIER, T. WELSH, A. WIMO, B. WINBLAD, L. FROELICH a S. ENGELBORGHS. Progress in the Treatment of Alzheimer's Disease Is Needed - Position Statement of European Alzheimer's Disease Consortium (EADC) Investigators. \textit{JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE}. BASEL: SPRINGER BASEL AG, 2024, roč.~11, č.~5, s.~1212-1218. ISSN~2274-5807. Dostupné z: https://dx.doi.org/10.14283/jpad.2024.153.

Podrobný výpis o publikaci